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Enjeu: 
L'incidence d'insuffisance rénale terminale augmente d'environ 5-6% par année dans nos 
régions. L'une des causes majeures d'insuffisance rénale est la néphropathie diabétique qui 
représente selon les pays entre 25 et 40% des néphropathies terminales. La progression de la 
néphropathie diabétique peut être ralentie de manière efficace par un bon contrôle du diabète 
et de l'hypertension artérielle et par le blocage du système rénine-angiotensine. Néanmoins, 
malgré l'application stricte de ces thérapies préventives, la néphropathie de bons nombres de 
patients diabétiques continue de progresser. Il est donc important de développer de nouvelles 
stratégies permettant de préserver la fonction rénale des patients diabétiques soit en 
améliorant le contrôle de la pression artérielle soit en diminuant la protéinurie. 
Contexte: 
Il existe un certain nombre d'évidences expérimentales que le blocage des récepteurs de 
l'endothéline pourrait avoir un effet positif sur le devenir de la néphropathie diabétique en 
diminuant de manière efficace la protéinurie même chez des animaux déjà traités 
efficacement avec un bloqueur du système rénine-angiotensine. Dans des études de phase 2 
impliquant l'avosentan, un antagoniste des récepteurs de l'endothéline actuellement en cours 
de développement pour le traitement de la néphropathie diabétique, on a pu démontrer que cet 
antagoniste, prescrit à des doses oscillant entre 5 et 50 mg par jour per os, diminue la 
protéinurie d'environ 20-40% chez des patients déjà traités avec un IEC ou un antagoniste de 
!'angiotensine. Toutefois, une grande étude de phase III conduite avec ce médicament chez 
des patients diabétiques a du être interrompue précocement en raison de l'apparition 
d'oedèmes et d'une surcharge hydrosodée conduisant dans certains cas à une décompensation 
cardiaque aiguë. La rétention hydrosodée est un effet secondaire connu des antagonistes de 
l'endothéline déjà sur le marché. Toutefois, pour l'avosentan, on ne savait pas si des doses 
plus faibles du médicament avaient aussi un effet négative sur la balance hydrosodée. En 
outre, les mécanismes rénaux responsables de la rétention hydrosodée sont encore mal connus 
chez l'homme. C'est pourquoi, nous avons organisé et réalisé cette étude de pharmacologie 
clinique chez le volontaire sain posant 2 questions : 1) des doses faibles d' avosentan 
produisent-elles aussi une rétention hydrosodée chez l'homme? et 2) quels sont les 
mécanismes rénaux pouvant expliquer la rétention hydrosodée ? 
Cette thèse est donc une étude clinique de phase I testant chez 23 volontaires sains les effets 
rénaux de différentes doses d'avosentan ou d'un placebo pour établir la courbe dose-réponse 
des effets rénaux de ce médicament. L'idée était également de définir quelle dose est sure et 
bien tolérée pour être utilisée dans une nouvelle étude de phase II. L'avosentan a été 
administré par voie orale une fois par jour pendant 8 jours à des doses de 0.5, 1.5, 5 et 50 mg. 
Les effets rénaux hémodynamiques et tubulaires ont été étudiés chez chaque sujet lors de la 
première administration Gour 1) et après une semaine de traitement Gour 8). Le médicament a 
induit une prise de poids dose-dépendante déjà présente à 5 mg et maximale à 50 mg(+ 0.8 
kg au jour 8). Nous n'avons pas mesuré d'impact de l'avosentan sur l'hémodynamique rénale 
ni sur les électrolytes plasmatiques. En revanche, nous avons constaté une diminution dose-
dépendante de la fraction d'excrétion de sodium Gusqu'à-8.7% avec avosentan 50 mg). Cette 
diminution était en rapport avec une augmentation dose-dépendante de la réabsorption 
proximale de sodium. Nous avons également constaté une baisse de la pression artérielle aux 
doses élevées et une hémodilution marquée par une baisse de ! 'hématocrite suggérant une 
rétention hydrique à la plus haute dose. 
Nos résultats suggèrent donc que l'avosentan induit une rétention sodée rénale dose-
dépendante expliquée avant tout par une rétention du sodium au niveau du tubule proximal. 
Cet effet n'est pas observé à des doses plus basses que 5 mg chez le volontaire sain , 
suggérant que ce médicament devrait être évalué pour son activité réno-protectrice à des doses 
inférieures ou égales à 5 mg par jour. La raison pour laquelle les hautes doses produisent plus 
de rétention sodée est peut être liée à une perte de sélectivité pour les sous-types (A et B) de 
récepteurs à l'endothéline lorsque l'on administre des doses plus élevées que 5 mg. 
Perspectives : 
Les résultats de ce travail de thèse ont donc permis de caractériser les propriétés rénales d'un 
nouvel antagoniste des récepteurs de l'endothéline chez l'homme. Ces résultats ont aussi 
permis de guider le développement futur de ce médicament vers des doses plus faibles avec 
l'espoir de garder les effets bénéfiques sur la protéinurie tout en améliorant le profil de 
tolérance du médicament par l'utilisation de doses plus faibles. 
Dose-Dependent Acute and Sustained Renal 
Effects of the Endothelin Receptor Antagonist 
Avosentan in Healthy Subjects 
J Smolander1, B Vogt1, MMaillard1, C Zweiacker1, T Littke2, T Hengelage2 and M Burnier1 
The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual 
mechanisms of this effect are unclear. We conducted a placebo-controlled study in 23 healthy subjects to assess the renal 
effects of avosentan and the dose dependency of these effects. Oral avosentan was administered once daily for 8 days at 
doses of 0.5, 1.5, 5, and 50 mg. The drug induced a dose-dependent median increase in body weight, most pronounced at 
50 mg (0.8 kg on day 8). Avosentan did not affect renal hemodynamics or plasma electrolytes. A dose-dependent median 
reduction in the fractional renal excretion of sodium was found (up to 8.7% at avosentan 50 mg}; this reduction was 
paralleled by a dose-related increase in proximal sodium reabsorption. lt is suggested that avosentan dose-dependently 
induces sodium retention bythe kidney, mainlythrough proximal tubular effects. The potential clinical benefits of 
avosentan should therefore be investigated at doses of :55 mg. 
In humans, the endothelins (ETs) comprise three vasoactive 
peptides (ET-1, ET-2, and ET-3). 111e three ET isoforms bind to 
two cell-surface receptors, ET receptor subtypes A (ETA) and 
B (ET B). ET-1 has the highest affinity for the ET A receptor, fol-
lowed by ET-2 and ET-3, with ail ETs exhibiting equal affinity for 
the ET B receptor.1 Important fonctions of ET A and ETB receptors 
include vasoconstriction and vasodilatation, ET clearance, salt 
balance, cell proliferation, and extracellular matrix production.2 
ET-1 is the major and best-studied isofonn in humans, and it 
plays a significant role in the pathophysiology of a variety of 
diseases, such as hypertension, heartfailure, renal failure, and 
pulmonary disorders. 3- 5 Consequently, several selective and 
mixed (dual) ET-1 receptor antagonists have been developed 
or are in development for varions pathological conditions. 6 
Avosentan (SPP301) is an orally administered competitive 
antagonist ofET-1witha50- to 600-fold higher selectivity for 
the ETA than for the ETB receptor, depending on the recep-
tor binding assay used (O. Baltatu, personal communication). 
Following multiple oral administrations of up to 60 mg per 
day, the pharmacokinetics of avosentan and its hydroxymethyl 
metabolite (Ro 68-5925) are linear up to a dose of 40 mg. The 
terminal half-lives of avosentan and its metabolite are in the 
range of 7-1 Oh, whether after a single dose or after repeated 
doses. Urinary excretion rates for avosentan and its metabolite 
are <0.1 and <5%, respectively.7 The drug is in clinical develop-
ment for use in treating diabetic nephropathy.6 
Overexpression of ET-1 and ET receptors has been demon-
strated in diabetic nephropathy in glomeruli and tubular epi-
thelial cells;4 upregulation of the renal ET system exacerba tes 
proteinuria, 8 a powerful predictor of renal disease progression. 9 
Experimental data suggested that ET A receptor antagonists may 
preserve renal fonction in diabetic rats. 10 In fact, in pilot and 
dosage-finding studies, a reduction in urinary albumin excre-
tion in patients with diabetic nephropathy was demonstrated 
following chronic preferential selective ET A receptor blockade 
with avosentan.6•11 In a recent placebo-controlled multicenter 
phase III morbidity and mortality study, avosentan doses of25 
and 50 mg were administered once daily to patients with dia-
betic kidney disease. The study was stopped prematurely after 
18 months for safety reasons. Although avosentan significantly 
lowered proteinuria, there were noticeably more cardiovas-
cular events (i.e,, fluid overload and congestive heart failure) 
. in the avosentan groups than in the placebo group. 12 It was 
hypothesized that avosentan at the doses tested could trigger 
renal retention of sodium and water, leading to fluid overload, 
edema, and, secondarily, cardiovascular events. In fact, for sev-
eral ET receptor antagonists (ERAs), fluid retention resulting in 
edema, weight gain, and, in some cases, worsening of congestive 
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heart failure conditions was reported, thereby supporfü1g this 
hypothesis. 6 
These findings gave impetus to this mechanistic study, which 
was initiated to further investigate the safety findings in the 
avosentan phase III trial. A placebo-controlled crossover study 
was conducted in healthy male subjects to assess the acute and 
sustained renal effects of avosentan and the dose dependency 
of these effects. The specific objectives were (i) to determine the 
effects of avosentan on renal hemodynamics (i.e., glomerular 
filtration rate and effective renal plasma flow) and sodium excre-
tion, (ii) to evaluate the influence of avosentan on plasma and 
urinary electrolytes, and (iii) to characterize the systemic effects 
(blood pressure and heart rate) of avosentan. For this purpose, a 
wide range of avosentan doses (0.5-50 mg) were administered to 
the study subjects for 1 week on a once-daily regimen. 
RESULTS 
Avosentan induced a dose-dependent increase in body weight 
over the course of the study, the effect being most pronounced 
at a dose of 50 mg 1 ), with a median increase on day 8 of 
0.8kg (mean ± SD, 1.0 ± 1.0kg). At that time point, the changes 
in body weight were significantly different from 0 for those 
on 5- and 50-mg doses (P < 0.05). Avosentan doses of0.5 and 
1.5 mg had no effect on body weight. No acute (day 1) changes 
in hemoglobin or hematocrit were observed after administra-
tion of avosentan, despite the protocol-defined acute water load. 
However, on day 8, a dose-dependent decrease in hemoglobin 
and, to a lesser degree, hematocrit was found (for both, P < 0.01 
for trend), with a marked hemodilution induced by the 50-mg 
dose 2 ); the changes from baseline were virtùally identi-
cal if analyzed on the basis of mean values (data not shown). 
Avosentan caused a dose-dependent decrease in diastolic 
blood pressure as compared to baseline, both on day 1 and 
day 8 (P < 0.01 for trend) l). For those on a dose of 
50 mg avosentan, the maximum median absolu te decrease 
amounted to 11.5 mm Hg (at 2 h after the dose on day 8). This 
was also refiected in mean and median diastolic blood pres-
sure areas under the curve (AU Cs), which decreased over the 
course of the study and (on the basis ofleast-squares me ans 
from the analysis of variance) were significantly lower on day 8 
max 
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Figure 1 Change from baseline in body weight after multiple oral 
administrations of avosentan or placebo. Values were determined on day 8. 
n = 8-9 per group. *Mean and median significantly different from 0 (P < 0.05, 
one sample t-test and Wilcoxon signed-rank test, respectively). 
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as compared to placebo for both the 5 mg ( difference in least-
squares means, 36.7h·mm Hg; P = 0.018) and the 50-mg doses 
(difference, 49.2h·mm Hg; P = 0.004). Avosentan doses <5mg 
had no sustained effect on diastolic blood pressure AUC. '111ere 
were no clear or consistent effects of avosentan on heart rate or 
systolic blood pressure (data not shown). 
In terms of renal hemodynamic parameters, no relevant 
changes or clear trends were observed over the course of the 
study Likewise, plasma electrolytes were not affected 
by avosentan treatment. In particular, plasma sodium concentra-
tions remained essentially stable over the duration of the study 
(data not shown). 
On day 1, dose-dependent changes in urinary sodium excre-
tion and fractional excretion (FE) of sodium (FENa) were found. 
In the placebo group, the ingestion of fluids before and after 
intake of study medication increased sodium excretion, as 
reflected by the increase in FENa (mean ± SD, 0.8 ± 0.9% at 6 h). 
Avosentari showed a dose-dependent effect on sodium excre-
tion. Specifically, mean ± SD of absolute changes from baseline 
in FENa for the 0.5-, 1.5-, 5-, and 50-mg doses at 6 h after dosing 
were 0.9 ± 0.8, 0.6 ± 0.4, 0.3 ± 0.2, and -0.2 ± 1.0%, respectively 
(P < 0.01 for trend). On day 8, this effect was still present but 
was less pronounced because a-new sodium balance had been 
reached The reduction in FENa was associated with 
a dose-dependent increase in proximal reabsorption of sodium 
on days 1 and 8, as reflected by decreases in the FE oflithium 
at most avosentan dosages On day l, mean ± SD of 
absolute changes from baseline in FEu for the 0.5-, 1.5-, 5-, and 
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Figure 2 Median changes from baseline in (a) hemoglobin and 
(b) hematocrit after single and repeated oral administrations of avosentan 
or placebo. Baseline was defined as the hemoglobin/hematocrit level 
measured at time 0 h on day 1 when the first dose of study medication was 
administered. n = 8-9 per group. 
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Table 1 Change from baseline in diastolic blood pressure following single and multiple oral administrations of avosentan or placebo 
-~~~-~ ~. ~·~--·· ~---~-~- -~~-~ 
0.5mg (n=9) 1.Smg (n =8) 5 mg (11 =9) 50mg (n =8) Placebo (n = 9) 
Day 1, 4h aa 0.22± 14.8 (-3.0) -0.13± 7.0 (0) -4.00± 9.3 (-5.0) -6.63±4.6** (-8.0) -0.67 ± 6.2 (-1.0) 
5.44±6.1 (3.0) Day 1, 6 h aa 3.33 ± 9.8 (6.0) 
Day 8, predose -3.67±9.5 (-2.0) 
Day8,4haa -3.22± 13.3 (-1.0) 
Day 8, 6h aa -0.56 ± 10.3 (0) 
3.13 ± 5.2 (3.5) -3.33±8.1 (-5.0) 
-5.13±11.2 (-4.0) -7.22± 8.0* (-8.0) 
-2.88±8.4(-3.5) -3.33 ± 6.8 (-3.0) 
-3.63 ± 8.3 (-3.5) -4.56±6'.2 (-8.0) 
-3.13± 5.8 (-2.5) 
-9.50±4.2** (-10.0) 
-10.5 ± 5.3** (-9.5) 
-11.8±5.4** (-11.0) 
0.11±9.4 (-2.0) 
2.11± 4.5 (1.0) 
4.22 ± 7.4 (3.0) 
Data are given in mm Hg. Ali values are presented as mean ± SD (median). Baseline was assessed before first dosing on day 1. 
aa, after administration. 
*P < 0.05, **P < 0.01: one sample t-test vs. hypothetical Ovalue representing no change in blood pressure, 
Renal hemodynamic and multiple oral administrations of avosentan or placebo 
0.5mg(n=9) 1.5mg (n=8) 5mg (n=9) 50mg(n=8) Placebo (n = 9) 
GFR 
Day 1, predose 114.6±18.1 (114.0) 127.3±12.3 (128.5.0) 108.3± 12.9 (107.0) 116.5±9.1 (119.5) 106.9 ± 45.5 (110.0) 
Day 1,6h aa 122.1 ±33.7(115.0) 130.8 ± 26.6 (131.5) 102.0±25.1 (104.0) 123.5±40.8 (112.5) 99.9 ± 39.9 (97.0) 
Day 8, predose 130.0 ± 38.3 (121.0) 130.8± 51.5 (117.5) 113.4± 21.7 (116.0) 100.5±36.7 (112.0) 121.7 ±28.3 (119.0) 
Day 8, 6 h aa 110.2±16.2 (105.0) 113.0± 16.8 (113.0) 115.7 ± 32.0 (109.0) 99.0± 14.9 (95.5) 110.7±17.6 (107.0) 
ERPF 
Day 1, predose 625.8 ± 158.8 (616.0) 728.0±192.3 (734.5) 580.3 ± 82.5 (555.0) 649.8 ± 149.7 (583.5) 596.7 ± 233.3 (636.0) 
Day 1, 6h aa 666.7 ± 230.1 (599.0) 754.3 ± 227.7 (733.0) 599.2±112.8 (650.0) 720.8 ± 207.6 (701.0) 653.2±283.0 (639.0) 
Day 8, predose 691.8 ± 244.3 (653.0) 747.5 ± 290.5 (765.0) 706.9±177.9 (698.0) 643.0 ± 309.9 (680.0) 750.0 ± 173.3 (799.0) 
Day 8, 6 h aa 608.2 ± 120.3 (560.0) 678.6± 195.7 (665.0) 767.9± 201.3 (685.0) 724.0 ± 220. 7 {705.5) 753.9± 176.3 (665.0) 
Data are given in ml/min. Ali values are presented as mean ± SD (median). There were no significant differences between groups. 
aa, after administration; ERPF, effective renal plasma flow; GFR, glomerular filtration rate. 
--0.5 0.5mg 1.5 mg 5mg 50mg Placebo 
Figure 3 Median absolute change from base li ne in fractional excretion 
of sodium after single and multiple oral administrations of avosentan or 
placebo. Values were determined at 6 h after the dose; baseline was assessed 
before first dosing on day 1. n = 7-9 per group. 
50-mg doses and placebo at 6 h after dosing amounted to 1.4 ± 
8.2, -3.0 ± 7.4, -2.3 ± 4.7, -8.7 ± 7.4, and -0.6 ± 9.8%, respec-
tively (P < 0.05 for trend). Avosentan had no significant effect 
on urinary excretion ofother electrolytes, phosphate, uric acid, 
or creatinine over the course of the study. 
Pharmacokinetics 
The main pharmacokinetic parameters of avosentan are 
summarized in After single-dose administration of 
0.5, 1.5, 5, or 50 mg, there was a dose-proportional increase 
in rate (peak plasma concentration) and extent (AUC0_t) of 
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Figure 4 Median absolute change from baseline in fractional excretion of 
lithium after single and multiple oral administrations of avosentan or placebo. 
Values were determined at 6 h after the dose; baseline was assessed before 
first dosing on day 1. n = 8-9 per group. 
avosentan absorption. Following multiple-dose administration, 
dose proportionality was observed up to a dose of 5 mg. There 
was no significant accumulation of avosentan after repeated 
administrations. 
Tolerability 
No unexpected or serions adverse events were observed. Twenty 
subj ects reported a total of 92 adverse events (AEs) of mostly 
mild to moderate severity, of which headaches and hot flushes 
were the most common. For these AEs, it was apparent that 
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Table.3 Main pharmacokinetic parameters of avosentan following single and multiple oral administrations of different doses 
in healthyvolunteers 
···-~····-· -·····~···· 
0.5mg(n=9) 1.5 mg (n=8) 5mg (n=9) 50mg(n=8) 
Day1 
tmax(h) 2.0 (1.9-5.9) 4.0 (1.9-5.9) 2.0(1.9-5.9) 2.0(1.9-4.1) 
cmax(ng/ml) 15.4± 1.2 (14.7) 48.2 ± 1.3 (53.8) 174.S ± 1.5 (184). 2,253±1.4 (2,369) 
AUC0.t (h·ng/ml) 204± 1.3 (199) 672±1.4(710) 2,065 ± 1.6 (2,216) 24,091±1.3 (24,835) 
DayB 
2.0 (2.0-4.0) 4.0(1.9-4.1) 3.9 (1.9-5.9) 1.9(1.8-4.0) 
19.6± 1.2 (17.4) 54.3 ± 1.2 (56.2) 228.9 ± 1.6 {206) 1,883.7±1.3 (1,938) 
641±1.4 (656) 2, 106± 1.4 (2,121) 15,646± 1.3 (14,985) 
Data are median (range) for tmax and geometric mean ±geometric SD (median) forthe other parameters. 
AUCo.t, area under the curve from 0 to the last quantifiable concentration; Cmax' peak plasma concentration; tmax' time to peak plasma concentration. 
the frequency of occurrence was dose dependent. Headaches 
and hot flushes were most frequently recorded in the avosen · 
tan 50-mg group (headache, 46; hot flushes,"10), followed by 
the 5-mg group (headache, 8). No headaches or hot flushes 
were reported with avosentan l.5mg or placebo. Two episodes 
of periorbital edema were reported in two subjects receiving 
avosentan 50 mg. TI1ere were no clinically relevant changes in 
vital signs, electrocardiograms, or clinical laboratory parameters 
over the course ·of the study. 
DISCUSSION 
This study, the first to explore the dose-dependent effects of 
the ERA avosentan on renal and systemic hemodynamics, 
examined plasma and urinary electrolytes, with a particular 
emphasis on renal sodium handling. The study was triggered 
by the premature termination of a phase III trial as a result 
of an increased incidence of fluid overload and congestive 
heart failure at avosentan doses of 25 and 50 mg. 12 In our 
mechanistic study in healthy subjects, we found that avosen-
tan induced an increase in body weight suggestive of fluid 
retention, the effect being most pronounced at high doses. 
Hemodilution was seen, particularly at the 50-mg dose. TI1is 
was apparently due to isotonie fluid retention, given that no 
changes in plasma sodium were noted. Avosentan doses of 
5 and 50 mg induced dose-dependent decreases in diastolic 
blood pressure, suggesting peripheral vasodilation. No reflex 
tachycardia was observed. Avosentan had no influence on 
renal hemodynamics, but a dose-dependent decrease in frac-
tional urinary sodium excretion was found, suggesting that 
avosentan has effects on sodium retention at higher dosages. 
Tiüs decrease was less pronounced after multiple avosentan 
dosing, suggesting that a new sodium balance was achieved 
over time, most likely resulting from an adaptation in sodium 
excretion by the distal convoluted tubules of the nephron. An 
examination of the effects of avosentan on segmental renaL 
sodium handling showed a dose-dependent increase in proxi-
mal sodium reabsorption. Finally, avosentan was generally 
well tolerated at low doses; cerebral vasodilation may have 
caused the moderate headaches reported by subjects at higher 
avosentan doses. 
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The results observed in our mechanistic study are consistent 
with published data on other ERAs. Both ETA and dual ET-1 
receptor antagonists can cause fluid retention. For instance, 
bosentan therapy was associated with worsening canges· 
tive heart failure, which was felt to be a consequence of fluid 
retention. 13•14 In addition, dose-dependent fluid retention has 
been reported for selective ET A receptor antagonists such as 
ambrisentan, sitaxsentan, and atrasentan. 6•15 In one study with 
atrasentan, two patients on a very high dosage (75 mg/day) 
developed severe hyponatretnia.16 Patients given lower doses 
had a 33% incidence of peripheral edema, which was associated 
with a 1-kg gain in body weight. 17 In the same study, a mild 
hemodilution effect was observed as a decrease in hemoglobin · 
concentrations. 
In the human kidney, ET A receptors are expressed in large 
quantities in cortical vessels, in pericytes of descending vasa 
recta, within glomeruli, and in interstitial cells from the inner 
and outer medulla. ET 8 receptors are most abundant in cells 
from the inner medullary collecting duct and in glomeruli.4 In 
the renal medulla, activation of ET 8 receptors abates sodium and 
water absorptioi1 and causes natriuresis and diuresis, whereas 
ET8 blockade appears to result in sodium and water retenti on. 4•18 
Consequently, the fluid retention observed with selective ET A 
receptor antagonists may be caused by some remaining activity 
on the ET 8 receptor. For avosentan, it has been suggested that 
it should be classified as a dual ERA rather than as a selective 
ET A receptor antagonist, given its weaker selectivity for the ET A 
receptor as compared to other selective ET A receptor antago· 
nists. 6 Therefore, avosentan's effect of promoting sodium reten-
tion when administered at a dose of 50 mg may originate from 
ET 8 blockade in the kidney caused by a loss of receptor selectiv-
ity at high doses. It is known that ET 8 receptors are also located 
on the proximal tubule, and this is in agreement with our study 
results using endogenous lithium clearance. Tiüs suggests that 
the observed water retention was promoted mainly by the proxi· 
mal tubular effects of avosentan on sodium handling. Yet an 
effect on distal tubular sodium reabsorption cannot be entirely 
ruled out. Of note, proximal tubules carry no ET A receptors. 18- 20 
However, given that ETA receptors may exert a natriuretic effect 
in female subjects, as has recently been described,21 there may 
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be gender-related differences in the effect ofERAs on sodium 
reabsorption. Moreover, fluid retention has been reported to 
occur even with a highly selective ET A receptor antagonist such 
as sitaxsentan.22 Therefore, one cannot exclude the possibility 
that ET A receptor blockade perse promotes sodium retention. 
Finally, ET A receptor antagonism is associated with peripheral 
vasodilation,23 which may be a contributory factor for the fluid 
retention observed after high doses of avosentan. Vasodilation 
may be associated with fluid shift into the extravascular space, 
thereby causing or worsening sodium and water retention. In 
the clinical setting, this might be even more pronounced, as 
. indicated by investigations in binephrectomized rats receiving 
increasing doses of avosentan. 'The rats showed a concentration-
dependent extravasation of fluid, as measured by changes in 
hematocrit, most likely caused by increased vascular perme-
ability or a precapillary vasodilation as observed with peripheral 
vasodilators. 24 
Most studies in healthy humans have not demonstrated an 
effect of selective ETA or dual ET-1 receptor antagonists on renal 
hemodynamics, thereby suggesting that ET-1, acting through 
the ET A receptor, does not contribute to the maintenance of 
renal vascular toue in health.8 This is in accord with the results 
of our study. 
With respect to systemic hemodynamics, the observed reduc-
tion in diastolic blood pressure may be explained on the basis 
ofvasoactive changes induced by avosentan. It has previously 
been reported, in both healthy subjects and patients, that ET A 
receptor blockade decreases peripheral vascular resistance, a 
major determinant of diastolic blood pressure.25,26 Likewise, 
the reported AEs ofheadache and hot flushes are likely attrib-
utable to the vasodilating properties of avosentan. Both of these 
AEs are known to be associated with avosentan and other ERAs 
(ET A and dual antagonists).6,ll,lS,26 In and of itself, the acute 
decrease in blood pressure observed in our subjects at high doses 
of avosentan could also contribute to acute sodium retention by 
stimulating proximal sodium reabsorption. 
In conclusion, our data suggest that avosentan dose-depend-
ently induces sodium retention by the kidney (probably via 
proximal tubular effects). The maximum effect is observed at 
the 50-mg dose; some minor effects are apparent ev~n with the 
5-mg dose. Doses <5 mg are virtually never associated with such 
findings, thereby indicating that these low avosentan doses do 
not affect steady-state sodium handling. From these data, it can 
be inferred that the incidence of congestive heart failure and 
fluid overload observed in a phase III morbidity and mortality 
study at avosentan doses of 25 and 50 mg were most likely of 
renal origin, caused by the high doses administered. The data 
support further investigation of the antiproteinuric effect of 
avosentan at doses of ::;5 mg. 
METHODS 
Subjects. Twenty-three healthymale subjects were enrolled in this study; 
all were Caucasian. Their mean age was 25.8 years (range, 18-39 years), 
and mean body mass index was 23.7kg/m2 (range, 20.4-29.0kg/m2). All 
the subjects were considered to be healthy on the basis of medical his-
tory, physical examination, vital signs, routine blood and urine analyses, 
and an electrocardiogram, all assessed at a screening visit. One subject 
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withdrew consent afterperiod 1; the missing period 2 (avosentan 1.5 mg) 
was completed byareplacement subject. The studyprotocol was reviewed 
and approved by an investigational review board (Ethics Committee of 
the Canton de Vaud, Lausanne, Switzerland), and written consent was 
obtained from each volunteer after the nature, purpose, and potential 
risks of the study were explained. The trial was performed in accordance 
with the Declaration of Helsinki (Somerset West Amendment, 1996). 
Study design. This was an open-label, placebo-controlled, lwo-period 
crossover study conducted at the Nephrology Research Unit, Centre 
Hospitalier Universitaire Vaudois, Lausanne, Switzerland. The subjects 
were randomized to two groups of six treatment sequertces. Within each 
group, each volunteer received two different doses of avosentan ( either 
0.5 and 1.5 mg or 5 and 50 mg) or avosentan and placebo in a randomized 
fashion for 8 days; the two treatments/study periods were separated by 
a 10-day washout phase. Avosentan and placebo were administered as 
oral solutions on a once-daily treatment schedule. 
The volunleers were sludied on a high-salt diet, which commenced 
3 days before the first drug administration and was maintained during 
the course of the study. For this purpose, the subjects received salt tablets 
lobe laken wilh each meal. This resulted in an addilional daily sall load 
of 6 g sodium chloride (i.e., ~ 100 mmol sodium). Diet compliance was 
evaluated by means of24-h urine collections. The subjects were institu-
tionalized on study days 1 and 8 of each study period to assess the acute 
and sustained effects, respectively, of avosentan on renal hemodynamics 
and sodium balance. Consumption of alcohol- and xanthine-containing 
beverages was forbidden during the study. 
On day 1, the renal effects of avosentan were determined after an over-
night fast, as previously described.27,28 The subjects were studied while 
lhey were in the supine position ( excepl during voiding). They received 
a light breakfast foilowed by a snack 1 h before drug intake; thereafter, 
they fasted throughout the study procedure. 1\vo intravenous catheters 
were inserted into antecubital veins, one for the infusion of sinistrine and 
para-aminohippurate (PAH) in a glucose-saline solution and a second 
one into the contralateral forearm for blood drawing. After the inges-
tion of 400 ml of water, intravenous infusion of sinistrine and PAH was 
started; a fixed amount of fluid (150 ml/h) was given orally to sustain 
urine output. Two baseline urine collections of 1 h each were obtained 
before drug intake. At the end of these baseline periods (time 0), the vol-
unteers received the study medication. Blood pressure, heart rate, urinary 
excretion of electrolytes (sodium, potassium, chloride, calcium, endog-
enous trace lithium), phosphate, uric acid, and clearances of sinistrine 
and PAH to assess glomerular filtration rate and effective renal plasma 
flow, respectively, were measured twice before drug administration and 
at 2-h intervals for 6h thereafter. SiJ;nultaneously, blood samples were 
drawn for measuring electrolytes, sinistrine, and PAH. 
On days 2-7, the subjects attended the study center each morning 
for ambulatory visits during which the study medication was adminis-
tered under supervised conditions. Blood pressure and heart rate were 
recorded while subjects were in the supine position before the drug was 
given. Body weight and tolerability (AEs) were assessed daily. On day 8, 
assessments of renal clearances were repeated in the same manner as on 
day 1. On day 9, safety assessments similar to those performed at the 
screening visit were repeated. 
Calculation of renal parameters. Clearances were calculated according to 
the traditional formula: CLx = (Ux · V)/Px, in which Ux and Px represent 
urine and plasma concentrations, respectively. ofx, and Vis the urine 
flow rate in milliliters per minute. Fractional excrction was calculated 
as the clearance of x divided by the clearance of sinistrine or glomerular 
filtration rate, where x denotes lithium or sodium. The segmental renal 
sodium handling was measured via endogenous lithium clearance as a 
noninvasive marker of proximal sodium reabsorption.29 Blood pressure 
was measured by the converitional auscultatory method. 
Pharmacokinetic assessments. Blood samples were collected on days 
1 and 8 before drug intake and then at 2, 4, 6,.and 24h thereafter. 
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On day 8, additional blood samples Were collected at 8 and 10 h 
postdose. From the avosentan plasma concentration-time profile 
data, the peak plasma concentration, time to peak plasma concentra-
tion, and AUC from 0 to the last quantifiable concentration (AUC0_t) 
were derived. 
· Analytical methods, drugs, and chemicals. Plasma and urinary sinistrine 
concentrations were measured by a microadaptation of a diphenylamine 
procedure on a Technicon AutoAnalyzer (Technicon Instruments, 
· Tarrytown, NY). PAH and electrolyte concentrations were determined 
as published previously. 3° Calcium, phosphate, and uric acid were quan-
tified photometrically using Technicon RAXT (Technicon Instrument, 
Tarrytown, NY). Endogenous trace lithium was measured by graphite 
furnace atomic absorption spectrophotometry.31 
Avosentan and placebo were provided by Speedel Phanna (Base!, 
Switzerland). Sinistrine was purchased from Fresenius Kabi Austria 
· (Graz, Austria), and PAH (aminohippurate, sodium sait of para-
aminohippuric acid) was obtained from Merck (Whitehouse Station, 
NJ). Plasma concentrations of avosentan were determined using a vali-
dated liquid chromatography-tandem mass spectrometry assay32 slightly 
modified from the original method.33 The lower limit of quantification 
was0.5ng/ml. 
Data sets and statistical analysis. Two subjects participated in a sin-
gle period only. In addition, one subject was excluded from statistical 
analysis because of noncompliance with regular intake of sait tablets 
during one study period (placebo). Therefore, for statistical analy-
sis of pharmacodynamie data, there were the following numbers of 
evaluable subjects per treatment: placebo (n = 9), avosentan 0.5 mg 
(n = 9), avosentan 1.5 mg (n = 8), avosentan 5 mg (n = 9), and avosentan 
50 mg (n = 8); 43 treatment~ in total. For safety analysis, all 23 subjects 
were included. 
Descriptive statistics were used to summarize the pharmacodynamie 
end points (and their changes from baseline), AEs, and baseline char-
acteristics. Summary statistics included the mean, SD, and median for 
, continuo us variables, as well as frequency and proportion for categorical 
variables. cflle main goal of the slatislical analysis was to demohstrate the 
dose dependency of the renal and hemodynamic effects of avosentan. For 
these parameters, trend analyses for dose response were performed by 
means of ANOVA, with a value of P < 0.05 as the level of significance. In 
addition, the AU Cs from 0 to 6 h for systolic and diastolic blood pressures 
on days 1and8 were calctùated and compared by ANOVA between active 
treatments and placebo (P < 0.05). For body-weight changes, explora-
tive statistical analyses were performed using the one sample t-test and 
Wilcoxon signed-rank test as appropriate (P < 0.05). 
A total of20 evaluable subjects were planned for this study, but 
no formai sample size calculation was performed. Based on histori-
cal data,25•26 it was expected that this number would allow detec-
tion of a 20% difference in glomerular filtration rate or effective 
renal plasma flow between the active treatments and placebo with 
a 95% confidence. 
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